Psychiatry and Neurology, Neurology · Dallas, TX
NPI
1023083961
Since 2006
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
6080 N Central Expy Ste 100
Dallas, TX, 75206
Phone (214) 827-3610
Groups this clinician bills Medicare through
Medicare paid, 2024
$912K
36,309 services
Medicare patients, 2024
326
Average age 75
Drug cost, 2024
$2.1M
1,974 prescriptions
Company payments, 2025
$1,611
From 27 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Daragh Heitzman was code A9575 (injection, gadoterate meglumine, 0.1 ml), 11,490 times for 54 patients. In total Daragh Heitzman billed 36,309 services in 65 codes, and Medicare paid $912K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-09-02.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| A9575 Injection, gadoterate meglumine, 0.1 ml | Office | 11,490 | 54 | $0.09 | $1,045 |
| J0585 Injection, onabotulinumtoxina, 1 unit | Office | 7,200 | 13 | $4.97 | $36K |
| J0588 Injection, incobotulinumtoxin a, 1 unit | Office | 4,850 | 11 | $4.05 | $20K |
| 99215 Office E&M - Established | Office | 388 | 217 | $127.97 | $50K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 269 | 184 | $12.74 | $3,428 |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 158 | 77 | $49.27 | $7,785 |
| 94010 Pulmonary Function Testing | Office | 106 | 54 | $17.76 | $1,883 |
| 99205 Office E&M - New | Office | 104 | 104 | $155.88 | $16K |
| 99214 Office E&M - Established | Office | 99 | 88 | $91.33 | $9,041 |
| 95886 Electrical Nerve Conductivity | Office | 90 | 56 | $71.46 | $6,431 |
| G2212 Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 81 | 29 | $25.25 | $2,045 |
| 70553 MRI/MRA - Head and Neck | Office | 54 | 49 | $155.01 | $8,371 |
| 95874 Musculoskeletal | Office | 51 | 19 | $59.77 | $3,048 |
| 64616 Musculoskeletal | Office | 44 | 15 | $162.28 | $7,140 |
| 95885 Electrical Nerve Conductivity | Office | 43 | 23 | $47.02 | $2,022 |
By year: 2022 $957K for 42,733 services; 2023 $905K for 34,090 services; 2024 $912K for 36,309 services.
Medicare prescription drug claims, 2024
In 2024, the drug Daragh Heitzman prescribed most often to Medicare patients was Gabapentin, with 195 prescriptions and refills. In total Daragh Heitzman wrote 1,974 Medicare prescriptions that cost $2.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Gabapentin Generic | 195 | 360 | 59 | $3,721 |
| Carbidopa-Levodopa Carbidopa/Levodopa | 144 | 353 | 40 | $3,785 |
| Donepezil Hcl Generic | 132 | 357 | 46 | $2,002 |
| Memantine Hcl Generic | 118 | 280 | 37 | $4,129 |
| Riluzole Generic | 109 | 187 | 27 | $27K |
| Trazodone Hcl Generic | 106 | 148 | 22 | $603 |
| Escitalopram Oxalate Generic | 98 | 160 | 16 | $1,026 |
| Duloxetine Hcl Generic | 70 | 134 | 15 | $1,296 |
| Glycopyrrolate Generic | 67 | 138 | 23 | $4,542 |
| Clonazepam Generic | 63 | 65 | Under 11 | $582 |
| Pyridostigmine Bromide Generic | 60 | 141 | 15 | $7,572 |
| Propranolol Hcl Generic | 46 | 110 | 12 | $841 |
| Ropinirole Hcl Generic | 46 | 75 | 14 | $1,195 |
| Gamunex-C Immune Globul G/Gly/Iga Avg 46 | 44 | 44 | Under 11 | $458K |
| Baclofen Generic | 44 | 102 | 16 | $2,188 |
Brand drugs: 236 claims; generic drugs: 1,738 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Daragh Heitzman $1,611 ($1,611 in general payments such as food, travel and fees) from 27 companies. The largest payer was Abbvie Inc. with $330.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 19 | $330 |
| Teva Pharmaceuticals USA, Inc. TEVA | 5 | $147 |
| Eisai Inc. 4523.T | 3 | $95.81 |
| UCB, Inc. UCB.BR | 4 | $95.47 |
| Genentech USA, Inc. ROG.SW | 3 | $80.25 |
| Celgene Corporation BMY | 5 | $79.74 |
| TG Therapeutics, Inc. TGTX | 3 | $79.59 |
| Pfizer Inc. PFE | 5 | $75.22 |
| Neurocrine BioSciences, Inc. NBIX | 2 | $73.31 |
| Novartis Pharmaceuticals Corporation NVS | 4 | $67.93 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.